← Back to Search

Behavioural Intervention

Serious Game-based Intervention for Mild Cognitive Impairment

N/A
Recruiting
Led By Sunghoon I Lee, PhD
Research Sponsored by University of Massachusetts, Amherst
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Fifty-five years old and above
Be older than 18 years old
Must not have
Diagnosis of dementia
Major depression
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if playing Neuro-World games can help people with early memory and thinking problems by keeping their brains active and improving their memory and thinking skills.

Who is the study for?
This trial is for people over 55 with mild cognitive issues, scoring between 17 and 25 on the MoCA test. They must be able to use a computer for online games and assessments. It's not suitable for those with major depression, certain neurological conditions, severe hearing or vision loss, or significant arm impairments.
What is being tested?
The study tests 'Neuro-World' cognitive training games designed to help brain function in patients with mild cognitive impairment. Participants will play these games at home and communicate via videoconferencing for assessments.
What are the potential side effects?
Since this intervention involves playing online games designed to improve cognition, side effects are minimal but may include eye strain or fatigue from prolonged screen time.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 55 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with dementia.
Select...
I have been diagnosed with major depression.
Select...
I have severe difficulty using my arms or hands.
Select...
I do not have any major issues with my arms that would stop me from using a tablet.
Select...
I show signs of a specific type of dementia or movement disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Montreal Cognitive Assessment (MoCA)
Secondary study objectives
Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for mild cognitive impairment patients (ADCS/MCI/ADL24)
Digit Backward Span (DBS)
Digit Forward Span (DFS)
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Game InterventionExperimental Treatment1 Intervention
Study participants play Neuro-World 30 minutes per day, twice a week for 12 weeks in your home settings (24 times).
Group II: No InterventionActive Control1 Intervention
Study participants do not engage in any cognitive training.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Mild Cognitive Impairment (MCI) include cognitive stimulation and enhancement through structured mental exercises, such as those provided by Neuro-World cognitive training games. These treatments work by engaging the brain in targeted activities designed to improve cognitive functions like memory, attention, and problem-solving skills. The mechanisms of action involve neuroplasticity, where the brain forms new neural connections in response to mental challenges, and cognitive reserve, which helps the brain compensate for age-related changes and potential damage. This is crucial for MCI patients as it can slow the progression of cognitive decline, improve daily functioning, and enhance overall quality of life.

Find a Location

Who is running the clinical trial?

University of Massachusetts, AmherstLead Sponsor
81 Previous Clinical Trials
468,100 Total Patients Enrolled
Rutgers, The State University of New JerseyOTHER
449 Previous Clinical Trials
66,689 Total Patients Enrolled
Université de MontréalOTHER
221 Previous Clinical Trials
104,230 Total Patients Enrolled
~5 spots leftby Mar 2025